drugset

drugset / Trial / NCT05254925

Phototoxicity Potential of 6% Bemotrizinol

NCT05254925 ↗

Phase 2 Completed 34 enrolled dsm-firmenich Switzerland AG

Non-randomizedFactorialSingle-blindBasic science

Summary

Phototoxicity Potential of Bemotrizinol (6%)

Timeline

Start: 2022-02-28
Primary completion: 2022-03-03
Completion: 2022-04-03

Drugs

Evaluation	Drug	Modality	Dose	Route
Comparator	Bemotrizinol	Unknown	0.15 ml	Topical
Comparator	Bemotrizinol	Unknown	0.15 g	Topical

Indications